PD-217,014

From Wikipedia, the free encyclopedia

PD-217,014

Systematic (IUPAC) name
(1α,3α,5α)-3-aminomethyl-bicyclo[3.2.0]heptane-3-acetic acid
Clinical data
Legal status	?
Identifiers
CAS number	444088-20-4^Y
ATC code	?
ChemSpider	26333275
Chemical data
Formula	C₁₁H₁₉N O₂
Mol. mass	197.273 g/mol
SMILES COC(=O)CC2(CN)CC1CCC1C2
InChI InChI=1S/C11H19NO2/c1-14-10(13)6-11(7-12)4-8-2-3-9(8)5-11/h8-9H,2-7,12H2,1H3/t8-,9+,11+ Key:ASBDKEXHKWHAPE-JZYVYDRUSA-N

PD-217,014 is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α₂δ calcium channels (1 and 2). It was developed as a potentially more potent successor to gabapentin and pregabalin, along with several other analogues such as atagabalin and 4-methylpregabalin, but while PD-217,014 produces visceral analgesic effects in animal studies with higher potency and efficacy than gabapentin, it was not developed further for clinical use because of its comparatively more complex synthesis, compared to other related analogues.^[1]

References

↑ Ohashi K, Kawai M, Ninomiya N, Taylor C, Kurebayashi Y. Effect of a new alpha 2 delta ligand PD-217014 on visceral hypersensitivity induced by 2,4,6-trinitrobenzene sulfonic acid in rats. Pharmacology. 2008;81(2):144-50. PMID 17989503

Analgesics (N02A, N02B)

Opioids
See also: Opioids template

Opium & alkaloids thereof	Codeine^# Morphine^# Opium Laudanum Paregoric

Semi-synthetic opium derivatives	Acetyldihydrocodeine Benzylmorphine Buprenorphine Desomorphine Diacetylmorphine Dihydrocodeine Dihydromorphine Ethylmorphine Hydrocodone Hydromorphinol Hydromorphone Nicocodeine Nicodicodeine Nicomorphine Oxycodone Oxymorphone

Synthetic opioids	Alphaprodine Anileridine Butorphanol Dextromoramide Dextropropoxyphene Dezocine Fentanyl Ketobemidone Levorphanol Meptazinol Methadone Nalbuphine Pentazocine Pethidine Phenazocine Piminodine Piritramide Propiram Tapentadol Tilidine Tramadol

Pyrazolones

Cannabinoids

Anilides

Non-steroidal
anti-inflammatories
See also: NSAIDs template

Propionic acid class	Fenoprofen Flurbiprofen Ibuprofen^# Ketoprofen Naproxen Oxaprozin

Oxicam class	Meloxicam Piroxicam

Acetic acid class	Diclofenac Indometacin Ketorolac Nabumetone Sulindac Tolmetin

COX-2 inhibitors	Celecoxib Lumiracoxib Parecoxib Rofecoxib Valdecoxib

Anthranilic acid (fenamate) class	Meclofenamic acid Mefenamic acid

Salicylates	Aspirin (Acetylsalicylic acid)^# (+paracetamol/caffeine) Benorylate Diflunisal Ethenzamide Magnesium salicylate Salicin Salicylamide Salsalate Trisalate Wintergreen (Methyl salicylate)

Atypical, adjuvant and potentiators,
metabolic agents and miscellaneous

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

M: CNS

anat (n/s/m/p/4/e/b/d/c/a/f/l/g)/phys/devp

noco (m/d/e/h/v/s)/cong/tumr, sysi/epon, injr

proc, drug (N1A/2AB/C/3/4/7A/B/C/D)

v t e α₂δ VDCC ligands

4-Methylpregabalin Atagabalin Gabapentin Gabapentin enacarbil Imagabalin PD-200,347 PD-217,014 PD-299,685 Pregabalin

This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.